To become a better investors, you need to put together a winning team that includes a strong brokerage company in your corner. But how can you pick the right broker for your needs?
In the following video, Fool contributor and personal finance expert Dan Caplinger discusses the things to consider in choosing a broker. With so much riding on your choice, it's important to look beyond stock commissions to get a sense of the true costs that you'll pay for your portfolio. In addition, by evaluating research and other services that each broker offers, you can simplify your own finances by consolidating accounts at one broker if you want.
Commission-free ETFs are a key part of brokers' offerings. To learn more about a few ETFs that have great promise for delivering profits to shareholders, check out The Motley Fool's special free report, "3 ETFs Set to Soar." Just click here to access it now.
Best Forestry Stocks For 2015: Forest Laboratories Inc (FRX)
Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.
Aclidinium
In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.
Linaclotide
Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.
Viibryd
As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.
Daliresp
In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
Namenda
Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.
Bystolic
Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).
Savella
Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.
Teflaro
In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.
Avibactam
Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.
Lexapro
Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.
Cariprazine
Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.
Levomilnacipran
Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.
GRT 6005
In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.
TTP399
In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.
Azimilide
In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.
RGH-618
RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.
Advisors' Opinion:- [By Sean Williams]
Instead of Elan, I feel the struggling Forest Laboratories (NYSE: FRX ) would be the most qualified marketing partner to help Vascepa sales soar. Forest Labs is being hit hard by patent expirations, but would bring an experienced marketing staff to the table. In addition, it already has two FDA-approved cardiovascular drugs in Bystolic and Tiazac, which both work to treat high blood pressure. Partnering with Amarin would further strengthen its cardiovascular product offerings and help remove some of the marketing uncertainty and high costs currently plaguing Amarin's share price.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are Forest Laboratories Inc.(FRX), Coca-Cola Co.(KO) and Waste Management Inc.(WM)
- [By David Williamson and Michael Douglass]
The�Science Translational Medicine�journal recently published research about the generic antidepressant�citalopram, which was�developed�by Forest�Laboratories (NYSE: FRX ) �under the brand name Celexa, as a potential way to help slow down the�development�of Alzheimer's disease.
Best Forestry Stocks For 2015: Internet Initiative Japan Inc.(IIJI)
Internet Initiative Japan Inc., together with its subsidiaries, provides Internet connectivity, WAN, outsourcing, and systems integration services to customers primarily in Japan. Its Internet connectivity services include services for corporate use, such as IP services and data center connectivity services, broadband Internet connectivity services, dial-up access services, IIJ mobile services, and IIJ ISDN/F and IIJ line management/F services; and connectivity services for home use consisting of IIJ4U, IIJmio, and hi-ho. The company?s outsourcing services comprise security-related outsourcing services that protect customer network systems from unauthorized access and secure remote connections to internal networks; network-related outsourcing services, such as Internet-virtual private network, and router rental; server-related outsourcing services, including Web hosting, e-mail hosting, document storage, and streaming; data center-related outsourcing services consisting o f data center facility, and management and monitoring; and customer support and help desk solutions, and IP phone services. It also provides systems integration services, which include consulting, project planning, systems design, and development of network systems, primarily focusing on Internet business systems, and Intranet and Extranet corporate information systems; and systems operation and maintenance services. In addition, the company sells network-related equipment, as well as provides automated teller machine (ATM) services. As of June 30, 2011, it operated 9 points of presence (POPs) for dedicated access and 1 POP for nationwide dial-up access. The company also operates approximately 280 ATMs and 16 Internet data centers. Internet Initiative Japan Inc. was founded in 1992 and is headquartered in Tokyo, Japan.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Thursday morning, the telecommunications services sector proved to be a source of strength for the market. Leading the sector was strength from ARC Group Worldwide (NASDAQ: ARCW) and Internet Initiative Japan (NASDAQ: IIJI). In trading on Thursday, non-cyclical consumer goods & services shares were relative laggards, down on the day by about 0.43 percent. - [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Thursday, telecommunications services shares were relative leaders, up on the day by about 0.83 percent. Top gainers in the sector included Internet Initiative Japan (NASDAQ: IIJI), with shares up 9.5 percent, and RRSat Global Communications Network (NASDAQ: RRST), with shares up 4.9 percent. - [By Jake L'Ecuyer]
Telecommunications services sector was the leading decliner in the US market today. Top decliners in the sector included Internet Initiative Japan (NASDAQ: IIJI), off 3.7 percent, and BT Group plc (NYSE: BT), down around 2.7 percent.
Top China Stocks To Invest In 2015: 1st NRG Corp (FNRC)
1st NRG Corp., incorporated on January 18, 1988, is an exploration and production company. The Company is engaged in the development of the Clabaugh Ranch Field, which is a project developing and producing coal bed methane reserves (CBM). This project includes a development of 6,025 gross acres in the Powder River Basin in northeast Wyoming. The Company is expanding its activities into unconventional shale through a participation agreement covering approximately 7,000 acres initially and subsequently acquired acreage covering an Area of Mutual Interest in South Eastern Ohio. Its production revenues are entirely from the natural gas produced at Clabaugh Ranch.
The targeted coal seams in the Powder River Basin are part of the Tongue River Member of the Fort Union formation and have been mapped as natural resource developments and exploration have occurred throughout the region. The Company has 42 drilled wells, which have encountered developed coal seams in the Werner, Upper and Lower Smith, Wyodak/Anderson Lower, Gates and Wall formations. In total the Company has identified 515 separate coals seams for development of which only 126 (42 wells X 3 seams) have been completed.
Advisors' Opinion:- [By Peter Graham]
What�� the Catch With Quantum Energy Inc? According to various disclosures, transactions of $2k and $3.5k have or will occur to mention Quantum Energy in various investment newsletters. On Friday, Quantum Energy released the pricing of its recently announced $5,000,000 BDC funding to be arranged by Data Capital Corp (DCC) where the latter has agreed to assist the former in the formation of a Business Development Company (BDC) by forming Quantum Funding, Inc. as a BDC to raise an initial $5,000,000. Upon receipt of the funding, Quantum Funding, Inc. will then be acquired as a subsidiary by QEGY in a share exchange where the $5,000,000 subsidiary will be acquired for 10,000,000 shares of newly issued restricted common stock for a valuation of $0.50 cents per share. Otherwise and early in the month, Quantum Energy announced it was shifting its focus from the West Texas Barnett Shale fields to North Dakota with the opening of an office in Williston, North Dakota. However, a quick look on Google Finance (as there are no up to date financials on Yahoo! Finance) reveals Quantum Energy has no revenues; a net loss of $0.01M (most recent reported quarter), net income of $2.01M and a net loss of $0.02M for the past three fiscal quarters; and $0.01M in cash to cover $0.34M in current liabilities at the end of last August. Then again, the recent financing deal could get things moving for Quantum Energy next year.
1st NRG Corp (OTCMKTS: FNRC) Gives a Drilling and Production UpdateSmall cap 1st NRG Corp is an exploration and production company currently developing and producing coal bed methane reserves (CBM) in Wyoming. On Friday, 1st NRG Corp fell 25% to $0.0003 for a market cap of $5.02 million plus FNRC is down 97.1% since the start of the year and down 99.8% since July 2010 according to Google Finance.
Best Forestry Stocks For 2015: Sirius XM Radio Inc.(SIRI)
Sirius XM Radio Inc. provides satellite radio services in the United States and Canada. It broadcasts a programming lineup of approximately 135 channels of commercial-free music, sports, news and information, talk and entertainment, traffic, and weather on subscription fee basis through two satellite radio systems in the United States; and holds an interest in the satellite radio services offered in Canada. The company also simulcasts music and selected non-music channels over the Internet; and offers applications to allow consumers to access its Internet services on mobile devices. As of December 31, 2010, it had 20,190,964 subscribers. In addition, the company designs, establishes specifications, sources or specifies parts and components, and manages various aspects of the logistics and production of satellite radios; licenses its technology to various electronics manufacturers to develop, manufacture, and distribute radios under various brands; and imports radios distri buted through its Websites. The company?s satellite radios are primarily distributed through automakers, retailers, and its Websites. Further, it provides music services for commercial establishments; a satellite television service to offer music channels as part of certain programming packages on the DISH Network satellite television service; music and comedy channels to mobile phone users through mobile phone carriers; Backseat TV, a service offering television content designed primarily for children in the backseat of vehicles; Travel Link, a suite of data services that include graphical weather, fuel prices, sports schedules and scores, and movie listings; and real-time traffic and weather services. The company was formerly known as Sirius Satellite Radio Inc. and changed its name to Sirius XM Radio Inc. in August 2008. Sirius XM Radio Inc. was founded in 1990 and is headquartered in New York, New York.
Advisors' Opinion:- [By Laura Brodbeck]
Tuesday
Earnings Expected: Buffalo Wild Wings, Inc. (NASDAQ: BWLD), Hillenbrand Inc (NYSE: HI), Sirius XM Holdings Inc. (NASDAQ: SIRI) Economic Releases Expected: German retail sales, French consumer confidence, German unemployment rate, eurozone CPI, eurozone PPI, US trade balance, US redbookWednesday
Best Forestry Stocks For 2015: Dassault Systemes SA (DASTY.PK)
Dassault Systemes SA provides software solutions and consulting services. The Company�� global customer base includes companies primarily in 11 industrial sectors: automotive; industrial equipment; aerospace; consumer goods; consumer packaged goods; energy; high-tech; shipbuilding; life sciences; construction, and business services. It organizes its business and markets its products and services in two types of applications: the Product Lifecycle Management (PLM) market, to support product development, production, maintenance and lifecycle management, and the Mainstream three-dimensional (3D) market, which is primarily focused on product design. Its software applications address a range of products, from apparel, consumer goods, machine parts and semiconductors to automobiles, aircraft, ships and factories. In March 2011, the Company acquired Intercim. In April 2011, the Company acquired Enginuity PLM. On March 31, 2010, it acquired the IBM PLM. On June 8, 2010, the C ompany acquired Exalead, a French company providing Search Platforms and Search-Based Applications (SBA). In June 2010, the Company acquired Geensoft, a provider of embedded systems development solutions.
The Company has developed a software applications portfolio, organized in brands, in order to provide solutions responding to the requirements of product development: Design, Realistic Simulation, Digital Manufacturing and Production, Collaborative Innovation, and Lifelike Experiences. The Company�� principal brands include SolidWorks , CATIA, SIMULIA, DELMIA, ENOVIA and Universal Services.
SolidWorks
SolidWorks applications include 3D tools to design, manage, simulate, sustain and communicate. SolidWorks include 3D Design, Data management, Simulation and Environmental assessments. SolidWorks 3D�� include complex part and assembly modeling, production drawing creation, data management, design validation and simulation of motion, f low and structural performance, environmental impact evalu! at! ion and publishing. SolidWorks Data Management solutions enable control over all design information, eliminating concerns about version control or data loss. SolidWorks simulation technology ensures the quality and performance of the design before users commit to production. SolidWorks Sustainability technology enables users to assess the environmental impact of their design to create more sustainable products.
CATIA
CATIA is the Company�� PLM solution for 3D collaborative creation. CATIA addresses the complete product development process, from early product concept specification through product in service. CATIA V6 is designed to enable the spectrum of next generation collaborative virtual design. Its product portfolio is consists of four main domains, which include systems, shape design, mechanical design and equipment engineering. CATIA Systems captures, manages, and tracks product requirements with traceability, ensuring that early requiremen ts are met accurately all along the product development cycle. CATIA Shape provides a line of surfacing, reverse engineering, and visualization solutions to create, modify, and validate any type of complex shapes and help streamline the transition and collaboration among industrial designers. CATIA Mechanical delivers a collaborative and flexible design environment with concurrent engineering and change management through relational design. CATIA Equipment provides an integrated environment that enables the collaborative detailed design of electronic, electrical, and fluidic systems in context of a virtual product.
SIMULIA
SIMULIA provides a scalable portfolio of realistic simulation solutions designed to enable companies across a range of industries to improve product performance, reduce the number of physical prototypes and drive innovation. SIMULIA�� V6 portfolio spans include finite element analysis, multi-physics solutions, optimization analy sis, and simulation lifecycle management. Its finite e! lement! a! nalysis! software companies are able to create and test virtual prototypes of products and processes. Its multi-physics solutions enable companies to reach beyond the boundaries of a single domain. SIMULIA also provides design exploration and optimization technology, enabling designers and engineers to perform rapid trade-off studies of real-world behavior and accelerate product development. SIMULIA offers simulation lifecycle management, based upon the Company�� ENOVIA architecture offering an open collaborative platform for management of simulation data, processes and intellectual property.
DELMIA
DELMIA covers the Company�� PLM digital manufacturing solutions ranging from virtual process definition, workcell set-up, optimization, scheduling, and operation, to maintenance of real-time production systems. DELMIA V6 covers four principal domains, including Manufacturing planning, with 3D process and resource planning tools for creating and optimizing bu ild-to-order and lean production manufacturing systems; plant and resources engineering, with tools to virtually define and optimize manufacturing assets concurrently with manufacturing planning; program and control engineering, to virtually program, validate and simulate manufacturing systems for the virtual commissioning of production facilities, and control and production execution, which offers an accurate virtual production system to enable companies to track real time production activities, perform schedule changes, launch new programs and introduce model changeovers, and schedule maintenance operations.
ENOVIA
ENOVIA addresses business process needs across a broad spectrum of industries, managing simple, as well as engineered, complex products. The ENOVIA V6 products are organized by business processes, which include governance, global sourcing, global sourcing, and unified live collaboration. The Governance domain is designed to help compan ies launch enterprise new product introductions on! time and! ! on budget! . Governance includes these sub-processes: Requirements Management, Portfolio Configuration, Program Management, Decision Support Business Intelligence, and Compliance. The Global Sourcing domain allows companies to leverage supply chain capabilities throughout the product lifecycle. The IP Lifecycle domain helps eliminate costly product development errors as it is designed to enable improved cross-functional product design, manufacturing planning and performance simulation. The Unified Live Collaboration domain allows companies to deploy product lifecycle processes across the extended enterprise by providing a single, real-time view of information protocol (IP) across all business process domains, collaborative process management capabilities, and a service-oriented architecture that integrates with other enterprise system
The Company competes with Parametric Technology Corporation, ANSYS, Inc., MSC Software Corporation, Oracle Corporation, SAP AG, Siemens PLM Software, Adobe, Altair Engineering, Autonomy, Aveva, Bentley, Google, Intergraph, MathWorks, Nemetschek AG, Right Hemisphere, and Autodesk, Inc.
Advisors' Opinion:- [By Markus Aarnio]
Autodesk's competitors include Adobe Systems (ADBE), Dassault Systemes SA (DASTY.PK), and Parametric Technology Corporation (PMTC). Here is a table comparing these companies.
Best Forestry Stocks For 2015: Build-A-Bear Workshop Inc. (BBW)
Build-A-Bear Workshop, Inc. operates as a specialty retailer of plush animals and related products. The company�s merchandise comprises various styles of animals to be stuffed; clothing, shoes, and accessories for the stuffed animals; and other brand appropriate toy and accessory items. It also licenses its Build-A-Bear Workshop brand to third parties to manufacture and sell merchandise to other retailers. As of January 31, 2013, the company operated approximately 400 Build-A-Bear Workshop stores worldwide, including the company-owned stores in the United States, Puerto Rico, Canada, the United Kingdom, and Ireland, as well as franchised stores in Europe, Asia, Australia, Africa, the Middle East, Mexico, and South America. The company also sells its products through a Web store. Build-A-Bear Workshop, Inc. was founded in 1997 and is headquartered in St. Louis, Missouri.
Advisors' Opinion:- [By Tabitha Jean Naylor]
Build-A-Bear Workshop (NYSE: BBW).��Unlike traditional toy manufacturers that make toys and games and distribute them to retailers, Build-A-Bear has flipped the toy-making concept on its ear. The idea of making a stuffed animal from scratch has taken the toy market by storm, and has carved out a nice little niche market for the company.
- [By Ben Levisohn]
Hasbro’s strength hasn’t necessarily translated into gains for other toy makers. Mattel (MAT) has fallen 0.5% to $42.50, while Build-a-Bear Workshop (BBW) has dropped 2.1% to $7.03. LeapFrog Enterprises (LF), however, has gained 3.3% to $8.98.
Best Forestry Stocks For 2015: Destination Maternity Corporation(DEST)
Destination Maternity Corporation engages in the design and retail of maternity apparel. It offers casual and career wear, formal attire, lingerie, sportswear, and outerwear. As of September 30, 2011, the company operated 2,352 retail locations, including 658 stores in 50 states of the United States (U.S.), Puerto Rico, Guam, and Canada; and 1,694 leased departments located within department stores and baby specialty stores in the U.S. and Puerto Rico. It operates stores under the Motherhood Maternity, A Pea in the Pod, and Destination Maternity names. Motherhood Maternity brand serves the value-priced portion of the maternity apparel business with stores located in regional malls, strip and power centers, and central business districts. A Pea in the Pod brand serves the medium-priced and luxury portion of the maternity apparel business with stores located in regional malls, lifestyle centers, central business districts, and stand-alone stores. Destination Maternity brand provides Motherhood and Pea merchandise with stores located in regional malls and lifestyle centers. The company also sells its merchandise on the Internet through DestinationMaternity.com and brand-specific Web sites. In addition, Destination Maternity Corporation offers Two Hearts Maternity by Destination Maternity collection at Sears stores in the U.S. through a leased department relationship. Further, the company distributes its Oh Baby by Motherhood collection through a license arrangement at Kohl?s stores in the U.S. and through Kohls.com. Additionally, it had 66 international franchised locations comprised of 15 stand-alone stores in the Middle East and South Korea under the Destination Maternity name; and 51 shop-in-shop locations in India and South Korea. The company was formerly known as Mothers Work, Inc. and changed its name to Destination Maternity Corporation in December 2008. Destination Maternity Corporation was founded in 1980 and is headquartered in Philad elphia, Pennsylvania.
Advisors' Opinion:- [By Marc Bastow]
Maternity apparel designer and retailer Destination Maternity (DEST) raised its quarterly dividend 6.7% to 20 cents per share, payable on Mar. 28 to shareholders of record as of Mar 7.
DEST Dividend Yield: 2.96% - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Destination Maternity (Nasdaq: DEST ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment